by Jeffrey Cummings (Editor), Jefferson Kinney (Editor), Howard Fillit (Editor)
Alzheimer's Disease (AD) is a growing global public health
challenge. The development of new therapies is urgently needed, and a
complex ecosystem of organizations has grown to facilitate AD drug
discovery and development. Masterfully collating information on the
drug development ecosystem, this book emphasizes the contributions of
each aspect in the pipeline with a uniform approach to chapters,
enabling readers to access relevant information quickly. Topics covered
include the use of non-clinical laboratory studies, biomarker
development, artificial intelligence, design and management of clinical
trials, and funding and financing models. Also discussed is the
critical role of advocacy fundraising for drug development. With the
approval of aducanumab, the function of the ecosystem has become
apparent. This is a definitive overview of how the ecosystem works in
transferring an AD drug from its discovery in the laboratory through
clinical trial testing to regulatory review and eventual marketing.
Details:
Year: 2022
Language: English
Format: PDF
Publisher: Cambridge University Press
ISBNs: 1108838669, 978-1108838665, 9781108838665, B09SVBG8C4, 9781108983297, 9781108985154
